WO2008058897A3 - Diphyllin and other lignans as a medicament for v-atpase mediated disease - Google Patents

Diphyllin and other lignans as a medicament for v-atpase mediated disease Download PDF

Info

Publication number
WO2008058897A3
WO2008058897A3 PCT/EP2007/062081 EP2007062081W WO2008058897A3 WO 2008058897 A3 WO2008058897 A3 WO 2008058897A3 EP 2007062081 W EP2007062081 W EP 2007062081W WO 2008058897 A3 WO2008058897 A3 WO 2008058897A3
Authority
WO
WIPO (PCT)
Prior art keywords
diphyllin
medicament
lignans
mediated disease
atpase
Prior art date
Application number
PCT/EP2007/062081
Other languages
French (fr)
Other versions
WO2008058897A2 (en
Inventor
Mette Groendahl Soerensen
Kim Henriksen
Morten Asser Karsdal
Original Assignee
Nordic Bioscience As
Mette Groendahl Soerensen
Kim Henriksen
Morten Asser Karsdal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Bioscience As, Mette Groendahl Soerensen, Kim Henriksen, Morten Asser Karsdal filed Critical Nordic Bioscience As
Publication of WO2008058897A2 publication Critical patent/WO2008058897A2/en
Publication of WO2008058897A3 publication Critical patent/WO2008058897A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

A V-ATPase or gastric proton pump inhibiting lignan such as diphyllin and related glycosides and derivatives, for use as a medicament in the treatment of excessive osteoclast action or in the treatment of excessive gastric acidification, suitably of the general formula (I), wherein : Rb and Rc may together form an alkylene bridge; Rd and Re also may together form an alkylene bridge; and each dotted bond independently is present or absent; and wherein the lactone ring is optionally opened and is optionally esterified.
PCT/EP2007/062081 2006-11-17 2007-11-08 Diphyllin and other lignans as a medicament for v-atpase mediated disease WO2008058897A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0623012.2 2006-11-17
GBGB0623012.2A GB0623012D0 (en) 2006-11-17 2006-11-17 Diphyllin and other lignans as a medicament for V-ATPase mediated disease

Publications (2)

Publication Number Publication Date
WO2008058897A2 WO2008058897A2 (en) 2008-05-22
WO2008058897A3 true WO2008058897A3 (en) 2009-03-26

Family

ID=37605523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/062081 WO2008058897A2 (en) 2006-11-17 2007-11-08 Diphyllin and other lignans as a medicament for v-atpase mediated disease

Country Status (2)

Country Link
GB (1) GB0623012D0 (en)
WO (1) WO2008058897A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045451A1 (en) 2010-10-05 2012-04-12 Ludwig-Maximilians-Universitaet Muenchen Novel therapeutic treatment of progranulin-dependent diseases
CN102070645B (en) * 2011-01-07 2015-04-22 兰州大学 Deoxy-podophyllotoxin type compound and preparation and application thereof
JP5643123B2 (en) * 2011-01-21 2014-12-17 花王株式会社 Whitening agent
JP5588408B2 (en) * 2011-09-01 2014-09-10 花王株式会社 Whitening agent
US9339454B2 (en) 2011-01-21 2016-05-17 Kao Corporation Skin whitening agent
AU2012277481B2 (en) * 2011-06-30 2016-10-06 Godavari Biorefineries Limited Synthesis of cleistanthin A an derivatives thereof
CN102516333A (en) * 2011-12-09 2012-06-27 南通大学 Diphyllin1,2-trans-permethoxy glucoside, its preparation method and application thereof
CN104370982B (en) * 2014-05-19 2017-11-21 南开大学 A kind of diphyllin derivative and its production and use
CN107595838B (en) * 2017-09-13 2019-10-22 北京理工大学 A kind of Lignanoids compounds are preparing the application in anti-liver fiber drug
US11884653B2 (en) * 2018-03-19 2024-01-30 Purdue Research Foundation Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof
WO2019182947A1 (en) * 2018-03-19 2019-09-26 Purdue Research Foundation Arylnaphthalene compounds as vacuolar-atpase inhibitors and the use thereof
CN111303137B (en) * 2020-03-05 2022-02-01 南通大学 Diphyllin ether derivative and preparation method and application thereof
IL298120A (en) * 2020-05-11 2023-01-01 Godavari Biorefineries Ltd Use of compounds for treating viral infections
CN113018281B (en) * 2021-02-23 2023-02-03 中国人民解放军海军军医大学 Pellino1 natural small-molecule inhibitor and application thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3704247A (en) * 1967-03-30 1972-11-28 Katsura Munakata Method for synthesizing fish-killing substances,and fish killers
JPS6330443A (en) * 1986-07-23 1988-02-09 Tsumura Juntendo Inc Novel lignan derivative and antiulcerative containing same as active ingredient
JPH02300124A (en) * 1989-02-28 1990-12-12 Takeda Chem Ind Ltd Preventive and remedy for osteoporosis
JPH0381272A (en) * 1989-08-23 1991-04-05 Yamanouchi Pharmaceut Co Ltd New lignan compound
JPH03120264A (en) * 1989-10-03 1991-05-22 Yamanouchi Pharmaceut Co Ltd Novel lignan compound
JPH04211609A (en) * 1990-03-22 1992-08-03 Takeda Chem Ind Ltd Bone absorption inhibitor and naphthalene derivative
JPH0912592A (en) * 1995-06-26 1997-01-14 Taisho Pharmaceut Co Ltd Lignan compound
DE10204637A1 (en) * 2001-02-05 2002-11-07 Greither Salus Haus Dr Otto Pharmaceutical, nutritional or food additive composition containing gamma-linolenic acid, isoflavone and lignan, is effective e.g. against tumors, osteoporosis and premenstrual syndrome
US20030100514A1 (en) * 2001-11-26 2003-05-29 Markku Ahotupa Method of inhibiting overactivity of phagocytes or lymphocytes in an individual
DE10243730A1 (en) * 2002-09-20 2004-04-01 Hubert Wilhelm Prior Using seeds of Linum usitatissimum for oral treatment of degenerative joint disease, particularly arthritis, has analgesic and antiinflammatory effects
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2006072647A1 (en) * 2005-01-10 2006-07-13 Hormos Medical Ltd. The use of a lignan for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency
CN1958805A (en) * 2006-11-09 2007-05-09 中国科学院长春应用化学研究所 Method for biologic preparing 4, 4 dihydric bowel lactone from burdock glycoside
CN101002814A (en) * 2007-01-12 2007-07-25 苏州大学 Medical use of burdock total lignanoid

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3704247A (en) * 1967-03-30 1972-11-28 Katsura Munakata Method for synthesizing fish-killing substances,and fish killers
JPS6330443A (en) * 1986-07-23 1988-02-09 Tsumura Juntendo Inc Novel lignan derivative and antiulcerative containing same as active ingredient
JPH02300124A (en) * 1989-02-28 1990-12-12 Takeda Chem Ind Ltd Preventive and remedy for osteoporosis
JPH0381272A (en) * 1989-08-23 1991-04-05 Yamanouchi Pharmaceut Co Ltd New lignan compound
JPH03120264A (en) * 1989-10-03 1991-05-22 Yamanouchi Pharmaceut Co Ltd Novel lignan compound
JPH04211609A (en) * 1990-03-22 1992-08-03 Takeda Chem Ind Ltd Bone absorption inhibitor and naphthalene derivative
JPH0912592A (en) * 1995-06-26 1997-01-14 Taisho Pharmaceut Co Ltd Lignan compound
DE10204637A1 (en) * 2001-02-05 2002-11-07 Greither Salus Haus Dr Otto Pharmaceutical, nutritional or food additive composition containing gamma-linolenic acid, isoflavone and lignan, is effective e.g. against tumors, osteoporosis and premenstrual syndrome
US20030100514A1 (en) * 2001-11-26 2003-05-29 Markku Ahotupa Method of inhibiting overactivity of phagocytes or lymphocytes in an individual
DE10243730A1 (en) * 2002-09-20 2004-04-01 Hubert Wilhelm Prior Using seeds of Linum usitatissimum for oral treatment of degenerative joint disease, particularly arthritis, has analgesic and antiinflammatory effects
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2006072647A1 (en) * 2005-01-10 2006-07-13 Hormos Medical Ltd. The use of a lignan for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency
CN1958805A (en) * 2006-11-09 2007-05-09 中国科学院长春应用化学研究所 Method for biologic preparing 4, 4 dihydric bowel lactone from burdock glycoside
CN101002814A (en) * 2007-01-12 2007-07-25 苏州大学 Medical use of burdock total lignanoid

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANIANEYULU ET AL.: "New Lignans from the Heartwood of Cleistanthus collinus", TETRAHEDRON, vol. 37, no. 21, 1981, pages 3641 - 3652, XP002502258 *
CHEMICAL & PHARMACEUTICAL BULLETIN , 47(3), 369-374 CODEN: CPBTAL; ISSN: 0009-2363, 1999 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BABA, ATSUO ET AL: "Studies on disease-modifying antirheumatic drugs. III. Bone resorption inhibitory effects of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) and related compounds", XP002502260, retrieved from STN Database accession no. 1999:201176 *
DATABASE WPI Week 199105, Derwent World Patents Index; AN 1991-031960, XP002502263 *
DATABASE WPI Week 200775, Derwent World Patents Index; AN 2007-798533, XP002502261 *
DATABASE WPI Week 200804, Derwent World Patents Index; AN 2008-A50527, XP002502262, HUANG L; LI X; SHEN F; SHI Q; ZHANG Y, ZHU A: "Medical application of total lignan of actium lappoul linne" *
MEENAKSHI J; SHANMUGAM G: "Cleistanthin A, a Diphyllin Glycoside From Cleistanthus collinus, Is Cytotoxic to PHA-Stimulated (Proliferating) Human Lymphocytes", DRUG DEVELOPMENT RESEARCH, vol. 51, 2000, pages 187 - 190, XP002502259 *
SORENSEN METTE G ET AL: "Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 22, no. 10, October 2007 (2007-10-01), pages 1640 - 1648, XP002509256, ISSN: 0884-0431 *
WESTCOTT NEIL D ET AL: "Flax seed lignan in disease prevention and health promotion", PHYTOCHEMISTRY REVIEWS, vol. 2, no. 3, 2003, pages 401 - 417, XP002509257, ISSN: 1568-7767 *
YIN ET AL: "In vivo anti-osteoporotic activity of isotaxiresinol, a lignan from wood of Taxus yunnanensis", PHYTOMEDICINE, GUSTAV FISCHER VERLAG, STUTTGART, vol. 13, no. 1-2, 5 January 2006 (2006-01-05), pages 37 - 42, XP005213817, ISSN: 0944-7113 *

Also Published As

Publication number Publication date
GB0623012D0 (en) 2006-12-27
WO2008058897A2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
WO2008058897A3 (en) Diphyllin and other lignans as a medicament for v-atpase mediated disease
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007100902A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
WO2007089745A3 (en) Novel compounds with high therapeutic index
SG171649A1 (en) Dpp iv inhibitor formulations
NO20091655L (en) Substituted dihydropyrazolones for the treatment of cardiovascular and hematological diseases
WO2010036613A8 (en) Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2207035A3 (en) Methods for detecting a mycobacterium tuberculosis infection
NO20071343L (en) Substituted phenylaminothiazoles and their use
WO2009064460A3 (en) Gastrointestinal delivery systems
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
WO2007010034A3 (en) Ampholytic copolymer, production thereof, and use of the same
WO2008033351A3 (en) Multimodal abuse resistant and extended release formulations
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
WO2006129318A3 (en) Benzofuran derivatives with therapeutic activities
NO20091260L (en) Combination therapy for diabetes mellitus
WO2005097103A3 (en) Diabetes and metabolic syndrome therapy utilizing cathepsin b inhibitors
WO2007133562A3 (en) Monocyclic heteroaryl compounds
WO2007104780A3 (en) N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use
WO2006066227A3 (en) Ester derivatives of ascorbic and 2-keto acid saccharides
TW200604189A (en) Lipase inhibitor
WO2007130821A3 (en) Mglur5 modulators ii
WO2006042478A8 (en) Small-molecule inhibitors of coronaviral main protease, their preparation and use
WO2001000566A3 (en) Substituted phenoxyacetic acids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07822383

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07822383

Country of ref document: EP

Kind code of ref document: A2